Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16627153 | 0.92 | NR1H4 (0.33) | NR1H4MRGPRX4MAPTRXFP1 | |
| SCHEMBL16910785 | 0.91 | MAPT (0.33) | NR1H4MRGPRX4KDM4EMEN1CYP1A2 | |
| SCHEMBL16627181 | 0.91 | MRGPRX4 (0.32) | MRGPRX4KDM4EMEN1CYP1A2MAPT | |
| SCHEMBL16627168 | 0.91 | NR1H4 (0.37) | NR1H4MRGPRX4MAPT | |
| SCHEMBL16911168 | 0.90 | MEN1 (0.33) | MRGPRX4KDM4EMEN1CYP1A2MAPT | |
| SCHEMBL18831221 | 0.90 | MRGPRX4 (0.33) | NR1H4MRGPRX4KDM4EMEN1CYP1A2 | |
| SCHEMBL16911097 | 0.90 | NR1H4 (0.32) | NR1H4MRGPRX4 | |
| SCHEMBL16911299 | 0.90 | NR1H4 (0.32) | NR1H4MRGPRX4KDM4EMEN1CYP1A2 | |
| SCHEMBL16627154 | 0.90 | TP53 (0.33) | NR1H4MRGPRX4KDM4EMEN1CYP1A2 | |
| SCHEMBL16911787 | 0.90 | PTGER1 (0.35) | NR1H4MRGPRX4MEN1MAPTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828389-B2 | Tetrazolinone compounds and their use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9828389-B2 | Tetrazolinone compounds and their use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9828389-B2 | Tetrazolinone compounds and their use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-28 | — | — | US | disclosed |
| EP-2900655-B1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2017-05-10 | — | — | EP | disclosed |
| EP-2900655-B1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2017-05-10 | — | — | EP | disclosed |
| US-20150203511-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150203511-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150203511-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-23 | — | — | US | disclosed |
| WO-2015050040-A1 | PLANT DISEASE CONTROL COMPOSITION AND USE THEREOF | 住友化学株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203511-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | CYCS, MT-CO3, CYP4F11 | NR1H4 1326/4885MRGPRX4 1919/4885KDM4E 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.